Back to Journals » OncoTargets and Therapy » Volume 11

Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma

Authors Chen JW, Huang CQ, Chen K, Li SM, Zhang X, Cheng J, Cai MY, Xiao Y

Received 30 September 2017

Accepted for publication 3 December 2017

Published 19 January 2018 Volume 2018:11 Pages 441—448

DOI https://doi.org/10.2147/OTT.S152953

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz


Jiewei Chen,1,2,* Chuqiang Huang,3,* Keming Chen,1,2,* Shuman Li,1,2 Xinke Zhang,1,2 Jun Cheng,4 Muyan Cai,1,2 Yongbo Xiao1,2

1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 2Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 3Department of Pathology, Peking University Shenzhen Hospital, 4Department of Pathology, Shenzhen People’s Hospital, Shenzhen, People’s Republic of China

*These authors contributed equally to this work

Purpose: Limb-bud and heart (LBH) levels are correlated with adverse survival in several malignancies; however, their significance in hepatocellular carcinoma (HCC) remains unclear. The objective of this study was to determine the association between LBH status and clinical outcomes.
Methods: We selected 226 patients with HCC who were treated surgically between 2003 and 2010 at a single academic center. Immunohistochemistry (IHC) was used to detect the protein expression of LBH in HCC samples. Receiver operating characteristic (ROC) curve analysis, Spearman’s rank correlation, Kaplan–Meier plots, and the Cox proportional hazards regression model were used to analyze the data.
Results: A high expression of LBH was detected in 20 (8.8%) of 226 HCC samples. Correlation analysis demonstrated that LBH in HCC was significantly correlated with aspartate amino­transferase (AST)/alanine aminotransferase (ALT) levels and clinical stages (P<0.05). In the Kaplan–Meier analysis, the mean survival time of patients with low levels of LBH was longer than that for those with high levels of LBH (P<0.05). The 3-year overall survival rate was 20% for patients with HCC and high levels of LBH versus 67% for patients with HCC and low levels of LBH. In the multivariate analysis, AST/ALT level, clinical stage, tumor relapse, and the level of LBH were the independent prognostic factors for overall survival (P<0.05).
Conclusion: Overexpression of LBH might contribute to the development and progression of HCC. LBH could be a novel prognostic marker for HCC.

Keywords: LBH, hepatocellular carcinoma, immunohistochemistry, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]